Tricuspid valve Candida endocarditis. Successful treatment with valve-sparing debridement and antifungal chemotherapy in a multiorgan transplant recipient.
Tricuspid valve Candida albicans endocarditis developed in a multiple-organ transplant recipient six months after successful treatment of Candida peritonitis. She has had no recurrence or valvular incompetence two years after valve-sparing debridement of the vegetation and prolonged therapy with amphotericin B. This is the second report of long-term success following valve-sparing debridement for tricuspid valve Candida endocarditis. In selected patients without annular involvement or gross valve destruction, excision of the fungal vegetation may allow for long-term cure and a competent valve.
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000628:therapy*; D003131:Combined Modality Therapy; D003646:Debridement; D004696:Endocarditis / Q000209:etiology / Q000628:therapy*; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D016030:Kidney Transplantation; D016035:Pancreas Transplantation; D013997:Time Factors; D014261:Tricuspid Valve / Q000601:surgery*
D000935:Antifungal Agents; D000666:Amphotericin B; D007654:Ketoconazole